Ciprofibrate
AssetAlso called Lipanor, NSC-759617, WIN 35833, Modalim
PPARalpha agonist that modifies plasma lipids.
- Stage
- Approved
- Modality
- Small molecule
- Target
- PPARA
- 3
- Indications
- 1
- Trial
- 1
- Developer
Indications
3No named disease
Approved, 1985
Dyslipidemia
Phase 3, Completed, NCT00350038, clinicaltrials.gov, Oct 31, 2026
Hypertension
Phase 3, Completed, NCT00350038, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Target and mechanism1
- Owner and partners2
- Trials1
- Evidence for its targets1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.